Heron Therapeutics, Inc.
Heron Therapeutics is a commercial-stage biotech company developing therapeutic products using its Biochronomer technology. Products include SUSTOL for chemotherapy-induced nausea and vomiting, CINVANTI for highly emetogenic cancer chemotherapy, ZYNRELEF for pain management, and APONVIE for postoperative nausea and vomiting.
Overview
Strengths
- Consistent growth: revenue has compounded at 11.8% a year over 5 years, rising in 4 of them.
- Paying down debt: long-term debt fell by 20.0 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 9.1% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 16.5% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data